Skip to main content

Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study

Clinical and Translational Oncology volume 22, pages 1645–1650 (2020)Cite this article

Abstract

Objective

To clarify the prognostic role of human papilloma virus (HPV) status among patients with hypopharyngeal carcinoma.

Methods

Surveillance, Epidemiology and End Results (SEER) HPV head and neck cancer database has been accessed and cases with hypopharyngeal squamous cell carcinoma with known HPV status were retrieved. Kaplan–Meier survival estimates were used to evaluate the impact of HPV status on overall survival outcomes of included patients and multivariable cox regression analysis was used to assess the impact of HPV status on overall and head and neck cancer-specific survival.

Results

A total of 1157 patients’ records with hypopharyngeal carcinoma were included in the current analysis. Using Kaplan–Meier survival estimates, patients with HPV positive status seem to have better overall survival compared to patients with HPV negative status (P < 0.01). When stratified by stage, patients with HPV positive regional and distant disease have better overall survival compared to patients with HPV negative regional and distant disease (P < 0.01 for both categories). The same observation cannot be confirmed for patients with localized disease (P = 0.15). Using multivariable Cox regression analysis, HPV positive status seems to be associated with better overall survival (HR for HPV negative versus HPV positive status: 1.76; 95% CI 1.39–2.24; P < 0.01) and cancer-specific survival (HR for HPV negative versus HPV positive status: 1.54; 95% CI 1.12–2.11; P < 0.01).

Conclusions

Patients with HPV positive hypopharyngeal carcinoma seem to have better overall and cancer-specific survival compared to patients with HPV negative hypopharyngeal carcinoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Rettig EM, D'Souza G. Epidemiology of head and neck cancer. Surg Oncol Clin N Am. 2015;24(3):379–96.

    Article  Google Scholar 

  2. Cole L, Polfus L, Peters ES. Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995–2005. PLoS ONE ONE. 2012;7(3):e32657.

    CAS  Article  Google Scholar 

  3. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014;50(5):380–6.

    Article  Google Scholar 

  4. Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer. 2017;123(9):1566–75.

    CAS  Article  Google Scholar 

  5. Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer. J Natl Cancer Inst. 2015;107(12):djv344.

    Article  Google Scholar 

  6. Heath S, Willis V, Allan K, Purdie K, Harwood C, Shields P, et al. Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice. Clin Oncol (R Coll Radiol). 2012;24(1):e18–23.

    CAS  Article  Google Scholar 

  7. Bates JE, Morris CG, Hitchcock KE, Dziegielewski PT, Mendenhall WM, Amdur RJ. Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status. Radiother Oncol. 2019;140:6–9.

    Article  Google Scholar 

  8. https://seer.cancer.gov/seerstat/databases/hpv/index.html. Accessed 8 Nov 2019

  9. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.

    CAS  Article  Google Scholar 

  10. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9.

    Article  Google Scholar 

  11. Melkane AE, Auperin A, Saulnier P, Lacroix L, Vielh P, Casiraghi O, et al. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. Head Neck. 2014;36(2):257–65.

    Article  Google Scholar 

  12. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60.

    CAS  Article  Google Scholar 

  13. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50.

    CAS  Article  Google Scholar 

  14. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51.

    Article  Google Scholar 

  15. Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 2015;33(8):836–45.

    Article  Google Scholar 

  16. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7–28.

    Article  Google Scholar 

  17. Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36(3):262–7.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This study is based on the SEER HPV head and neck cancer database.

Author information

Authors and Affiliations

  1. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, T6G 1Z2, Canada

    O. Abdel-Rahman

Authors
  1. O. Abdel-Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Abdel-Rahman.

Ethics declarations

Conflict of interest

I have no conflicts of interest.

Research involving human participants and/or animals

This work does not involve human participants or animals.

Informed consent

This work is based on secondary analysis of publicly available dataset. Informed consent was not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 16 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abdel-Rahman, O. Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study. Clin Transl Oncol 22, 1645–1650 (2020). https://doi.org/10.1007/s12094-020-02289-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-020-02289-8

Keywords

  • HPV
  • Head and neck cancer
  • Hypopharyngeal carcinoma
  • Prognosis